Are immunoconjugates useful for therapy with autoimmune diseases?

International Journal of Immunopharmacology

Volumn 19, Issue 2, 1997, Pages 83-93

  Wu, Min ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Autoimmune diseases; Immunotoxins Immunoconjugates; Monoclonal antibody; Toxin therapy

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOTOXIN;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNITY; DRUG EFFICACY; DRUG TARGETING; DRUG THERAPY; FEVER; FLU LIKE SYNDROME; HEYMANN NEPHRITIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLOMERULONEPHRITIS; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYASTHENIA GRAVIS; PSORIASIS;

EID: 0030738952     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(97)00012-X     Document Type: Article

References (56)

1. 486IL-2) in rat adjuvant arthritis. Eur. J. Immunol., 22, 1673-1679.
2. Baekkeskov, S., Aanstoot, H. J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H. & Camilli, P. D. (1990) Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature, 347, 151-156.
3. 486-IL-2) results in specific deletion of antigen-activated T cell clones. J. Immunol., 145, 3535-3539.
4. Blank, M., Manosroi, J., Tomer, Y., Manosroi, A., Kopolovic, J., Charcon-polak, S. & Shoenfeld, Y. (1994) Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin. Exp. Immunol., 98, 434-441.
5. Brown, R. M. & Krolick, K. A. (1988) Selective idiotype suppression of an adoptive secondary anti-acetylcholine receptor antibody response by immunotoxin treatment before transfer. J. Immunol., 140, 893-898.
6. Cannon, G. W., Marble, D. A., Griffiths, M. M., Cole, B. C., McCall, S., Shulman, S. F. & Strand, V. (1995) Immunologie assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate. J. Rheumatol., 22, 207-213.
7. Choy, E.H.S., Kingsley, G.H. & Panayi, G.S. (1995) T-cell regulation. In Baillieres Clinical Rheumatology (eds Brooks, P.M. and Furst, D.E.), Vol. 9, pp. 653-671. Bailliere Tindall, London.
8. Cush, J. J., Olsen, N. J., Brooks, R. H., Nichols, L. A., Kavanaugh, A. F. & Lipsky, P. E. (1993) Cyclic anti-CD5 immunoconjugate therapy in early rheumatoid arthritis (RA). Arthritis Rheum., 36, S130.
9. Deshambo, R. M. & Krolick, K. A. (1986) Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using anti-idiotypic antibodies coupled to the A chain of ricin. J. Immunol., 137, 3135-3139.
10. Endo, Y., Mitsui, K., Motizuki, M. & Tsug, I. (1987) Mechanism of action of the toxic lectin ricin and related toxic lectins on eukaryotic ribosomes. J. Biol. Chem., 262, 5908-5912.
11. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med., 1, 442-447.
12. + lymphocytes. J. invest. Dermatol., 102, S531.
13. Kelly, V. E., Bacha, P., Pankwycz, O., Nichols, J. C., Murphy, J. R. & Strom, T. B. (1988) Interleukin-2 diphtheria toxin fusion protein abolish cell-mediated in vivo. Proc. Natl Acad. Sci. USA, 85, 3980-3984.
14. Kerjaschki, D. & Farquhar, M. Q. (1982) The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc. Natl Acad. Sci. USA, 79, 5557-5561.
15. Kolb, H., Kolb-Bachofen, V. & Roep, B. O. (1995) Autoimmune versus inflammatory type I diabetes: a controversy?. Immunol. Today, 16, 170-172.
16. Krolick, K. A., Thompson, P. A., Infante, A. J., Zoda, T. E., Brandon, K. M. (1995) Strategies for the inhibition of T cell responses involved in murine experimental myasthenia gravis using Vβ-specific immunotoxins and an antibody specific for CD40 ligand (anti-gp39). J. Cell Biochem., S21A, 146.
17. Krolick, K. A. (1989) Inhibition of autoimmue reactivity against acetylcholine receptor with idiotype-specific immunotoxins. Meth. Enzymol., 178, 448-455.
18. Kruegger, J.G. & Gottlieb, A.B. (1994) Growth factor, cytokines and eicosanoids (in psoriasis pathogenesis). In Psoriasis (ed. L. Dubertret), pp. 18-28. ISED, Brescia, Italy.
19. Like, A. A. & Rossini, A. A. (1976) Streptozotocin-induced pancreatic insultis: new model of diabetes mellitus. Science, 193, 415-417.
20. Martin, P., Nelson, B. & Friedmann, N. (1994) Xomazyme CD5-plus for treatment of acute graft-versus-host disease (GvHD): preliminary results of A randomized prospective study. Blood, 84(10s), A540.
21. Martin, P. J., Nelson, B. J., Appelbaum, F. R., Anasetti, C., Deeg, H. J., Hansen, J. A., McDonald, G. B., Nash, R. A., Sullivan, K. M., Witherspoon, R. P., Scannon, P. J., Friedmann, N. & Storb, R. (1996) Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogenic marrow transplantation. Blood, 88, 824-830.
22. Misquith, S. & Surolia, A. (1995) In vivo treatment of Heymann's Nephuritis using a cytotoxic protein-toxin conjugate. FEBS Lett., 373, 151-154.
23. 486 IL-2) in refractory rheumatoid arthritis. Arthritis Rheum., 38, 1177-1186.
24. Olsberg, C. A., Mikiten, T. M. & Krolick, K. A. (1985) Selective in vitro inhibition of an antibody response to purified acetylcholine receptor by using antigen-ricin A chain immunotoxin. J. Immunol., 135, 0062-3067.
25. Olsnes, S., Sandvig, K., Peterson, O. W. & Van Deurs, B. (1989) Immunotoxins-entry into cells and mechanisms of action. Immunol. Today, 10, 195-291.
26. Pai, L. H. & Pastan, I. (1993) Immuotoxin therapy for cancer. JAMA, 269, 78-81.
27. Pastan, I., Willingham, M. C. & FitzGerald, D. J. (1986) Immunotoxins. Cell, 47, 641-648.
28. Paulus, H. E., Egger, M. J., Ward, J. R., Williams, H. J. (1990) The Cooperative Systematic Studies of Rheumatic Disease Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the finding in patients treated with placebo. Arthritis Rheum., 33, 477-484.
29. Petzelbauer, P., Stingl, G., Wolff, K. & Volc-platzer, B. (1991) Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J. invest Dermatol., 96, 362-369.
30. Quiza, C. G., Leenaerts, P. L. & Hall, B. M. (1992) The role of T cells in the mediation of glomerular injury in Heymann's nephritis in the rat. Int. Immunol, 4, 423-432.
31. 389IL-2 in cultured hematopoietic cells. Cancer Res., 56, 2590-2595.
32. Reichmann, L., Clark, M., Waldmann, H. & Winter, G. (1988) Reshaping human antibodies for therapy. Nature, 332, 323-327.
33. 486IL-2 fusion toxin therapy in rheumatoid arthritis (RA). Arthritis Rheum., 36, s130.
34. 389IL-2, in rheumatoid arthritis. Arthritis Rheum., 36, S130.
35. 486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum., 36, 1223-1233.
36. Skyler, J. S., Lorenz, T. J., Schwartz, S., Eisenbarth, G. S., Einhorn, D., Palmer, J. P., Marks, J. B., Greenbaum, C., Saria, E. A. & Byers, V. (1993) Effects of an anti-CD5 immunoconjugate (CD5 plus) in recent-onset Type-I-diabetes-mellitus-a preliminary investigation. J. Diabetes Compile., 7, 224-232.
37. Smith, D. H., Byrn, R. A., Marsters, S. A., Gregory, T., Groopman, J. E. & Capon, D. J. (1987) Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science, 238, 1704-1707.
38. Song, Y. H., Li, Y. & Macloven, K. (1996) The nature if autoantigens targeted in autoimmune endocrine diseases. Immunol. Today, 17, 232-238.
39. Stafford, F. J., Fleisher, T. A., Lee, G., Brown, M., Strand, V., Austin III, H. A., Balow, J. E. & Klippel, J. H. (1994) A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic Lupus Erythematosus. J. Rheumatol., 21, 2068-2070.
40. Steinberger, I., Brenner, T., Loberboum-Galski, H. (1995) Interleukin-2 Pseudomonas extotoxin chimeric protein is cytotoxic to B cell cultures derived from myasthenia gravis patients. J. Neuro Sci., 133, 183-191.
41. Strand, V., Lipsky, P. E., Cannon, G. W., Calabrese, L. H., Wiesnhutter, C., Cohen, S. B., Oisen, N. J., Lee, M. L. & Lorenz, T. J. (1993) Nelson B and the CD5 plus Rhematoid Arthritis Investigators Group. Effects of administration of an anti-CD5 plus immunoconjugate. Arthritis Rheum., 36, 620-630.
42. Strom, T. B., Kelley, V. E., Murphy, J. R., Nichols, J. & Woodworth, T. G. (1993) Interleukin-2 receptor-directed therapies: antibody or cytokine-based targeting molecules. Ann. Rev. Med., 44, 343-353.
43. Till, M., Ghetie, V., Gregory, T., Patzer, E. J., Porter, J. P., Uhr, J. W., Capon, D. J. & Vitetta, E. S. (1988) HIV-infected cells are killed by rCD4-ricin A chain. Science, 242, 1166-1168.
44. Vallera, D. A., Carroll, S. F., Brief, S. & Blazar, B. R. (1992) Anti-CD3 immunotoxin prevents low-dose STZ/inteferon-induced autoimmune diabetes in mouse. Diabetes, 41, 457-464.
45. Vallera, D. A. (1994) Immunotoxins: will their clinical promise be fulfilled? Blood, 83, 309-317.
46. Vitetta, E. S., Thorpe, P. E. & Uhr, J. W. (1993) Immunotoxins: magic bullets or misguided missiles. Immunol. Today, 14, 252-259.
47. Vitetta, E. S. (1990) Immunotoxins: new therapeutic reagents for autoimmunity, Cancer, and AIDS. J. Clin. Immunol., 10, 15S-18S.
48. Wacholtz, M. C. & Lipsky, P. E. (1992) Treatment of lupus nephritis with CD5 plus; an immunoconjugates of an anti-CD5 monoclonal antibody and ricin A chain. Arthritis Rheum., 35, 837-839.
49. Wang, Q. C., Pai, L. H., Debinski, W., FitzGerald, D. J. & Pastan I. (1993) Polyethylene glycol-modified chimeric toxin composed of transforming growth factor-alpha and pseudomonas Exotoxin. Cancer Res., 53, 4588-4594.
50. 486IL-2 (IL-2 toxin) selectively inactivates high affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann. NY Acad. Sci., 636, 403-405.
51. Weinberg, A. D., Bourdette, D. N., Sullivan, T. J., Lemon, M., Wallin, J. J., Maziarz, R., Davey, M., Palida, F., Godfrey, W., Engleman, E., Fulton, R. J., Ofner, H. & Vandenbark, A. A. (1996) Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med., 2, 183-189.
52. Wofsy, D. & Seaman, W. E. (1987) Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J. Immunol., 138, 3247-3253.
53. Wu, M. (1997) Enhancement of immunotoxin activity by chemical and biologic reagents. Bri J Cancer, 75, 1347-1355.
54. Wu, M., Miyazawa, M. & Nose, M. (1993) Immunotoxins as a new reagent for treatment of viral infection and autoimmune diseases. Drug Deliv. Syst., 8, 5-10.
55. Zhang, G. X., Ma, C. G., Xiao, B. G., Bakhist, M., Ljungdahl, A., Olsson, T. & Link, H. (1995) Suppression of experimental autoimmune myasthenia-gravis after CD8 depletion is associated with decreased IFN-γ and IL-4. Scand. J. Immunol., 42, 457-465.
56. + T cells suppresses the development of experimental autoimmune myasthenia-gravis in lewis rats. Euro. J. Immunol., 25, 1191-1198.